Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Subscribe To Our Newsletter & Stay Updated